Move Starts To Strip Anticancer Drug Regulation From FDA After New Charges It Is Delaying INDs
In Brief: NCI Needs To Move Quicker On Funding Jot New Leads, Rauscher Says; Harley Dirks Quits
Frederick RFP Held Up; NCI Probably Will Reject Any Further Delay
Moloney Convinces Most NCAB Members Of Virus Program Value, Shubik Only Dissenter
King Tells Centers To Concentrate On Project Grants
First Lady Helps Dedicate New MDA Facilities
Disease Oriented Programs Must Be Coordinated: Rabson
Trending Stories
- Vinay Prasad’s CV inaccurately claims past membership on the President’s Cancer Panel
- FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.” - Breakthrough Therapy designation, ASCO plenary, and NEJM publication notwithstanding, breast cancer drug camizestrant gets a No from ODAC
- CBER Director Vinay Prasad dared to “say no to drugs”
- Prasad’s “deceit,” plus, ODAC’s tough decision against biomarker-based progression assessment (for now)
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members









